Enterprise Therapeutics vs Neuralink

Side-by-side comparison of AI visibility scores, market position, and capabilities

Neuralink leads in AI visibility (74 vs 35)
Enterprise Therapeutics logo

Enterprise Therapeutics

NicheLife Sciences & BioTech

Ion Channel Drug Discovery for Respiratory Disease

Enterprise Therapeutics is a UK-based drug discovery biotech targeting ion channels and mucus biology to treat cystic fibrosis, COPD, and non-CF bronchiectasis; raised ~£50M+ from Syncona and other VCs;

AI VisibilityBeta
Overall Score
D35
Category Rank
#160 of 198
AI Consensus
67%
Trend
stable
Per Platform
ChatGPT
30
Perplexity
41
Gemini
40

About

Enterprise Therapeutics is a British biotechnology company founded in 2012 and headquartered in Brighton, United Kingdom, focused on discovering and developing small-molecule drugs that target ion channels and mucus secretion biology in the airways. The company's scientific foundation draws on the biology of chloride and calcium-activated channels — particularly the TMEM16A chloride channel — which regulate mucus production and hydration in the lungs. Dysfunctional mucus clearance is a common pathological feature of cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and non-CF bronchiectasis, conditions that collectively affect tens of millions of patients globally. By modulating these channels with small molecules, Enterprise Therapeutics aims to develop treatments that restore airway surface liquid and improve mucociliary clearance independent of the genetic mutation driving the disease.

Full profile
Neuralink logo

Neuralink

LeaderLife Sciences & BioTech

Brain-Computer Interface

Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.

AI VisibilityBeta
Overall Score
B74
Category Rank
#3 of 198
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
72
Perplexity
80
Gemini
73

About

Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.

Full profile

AI Visibility Head-to-Head

35
Overall Score
74
#160
Category Rank
#3
67
AI Consensus
79
stable
Trend
stable
30
ChatGPT
72
41
Perplexity
80
40
Gemini
73
31
Claude
76
31
Grok
72

Key Details

Category
Ion Channel Drug Discovery for Respiratory Disease
Brain-Computer Interface
Tier
Niche
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.